Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma

Last updated: February 13, 2025
Sponsor: Intech Biopharm Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Asthma

Treatment

Albuterol Sulfate inhalation Placebo

Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation

Albuterol Sulfate inhalation aerosol 108 mcg per actuation

Clinical Study ID

NCT04912596
TW20-4643
  • Ages 20-65
  • All Genders

Study Summary

The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male, non-pregnant and non-lactating female subjects (20-65 years of age,inclusive).

  2. A clinical diagnosis of mild asthma with historical documentation of the asthmadiagnosis according to either: (1) the National Asthma Education and PreventionProgram (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA)Global Strategy for Asthma Management and Prevention (2020).

  3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening: Low doses of ICS alone, or in combination with SABA,used regularly with a stable regimen.

  4. Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of the local predicted normalvalue after withholding SABA ≥ 8 hours.

  5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 ≤ 8 mg/mL.

  6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack-years (the equivalent of one pack per day for 5 years).

  7. Provision of written informed consent.

  8. Other than asthma, in general good health.

  9. Body mass index (BMI) between 17 and 35 kg/m2 (inclusive).

  10. Able to correctly use MDI inhalers.

  11. Able to perform valid and reproducible pulmonary function tests including noevidence of spirometry effort-induced bronchoconstriction.

  12. If the subject or subject's partner is of child-bearing potential, a medicallyacceptable form of contraception will be used for the duration of the study.Medically acceptable contraceptives include: (1) surgical sterilization, (2) HealthAuthority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.

Exclusion

Exclusion Criteria:

  1. Evidence of conditions altering airway reactivity to methacholine, including upperor lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergicrhinitis, sinobronchitis, etc.) within 6 weeks before Screening.

  2. Evidence of a baseline FEV1 < 60% of the local predicted normal value or FEV1 < 1.5L.

  3. History of seasonal asthma exacerbations, in which case the subject should bestudied outside of the relevant allergen season.

  4. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseasesincluding COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma,pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator,would compromise subject safety or interfere with the evaluations.

  5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric,endocrine dysfunction, including ECG with evidence of ischemic heart diseases andsignificant arrhythmias.

  6. Treatment in an emergency room or hospitalization for acute asthmatic symptomswithin 3 months prior to screening.

  7. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2receptor-agonist drug, HFA, any related compounds or methacholine.

  8. Need for daily oral corticosteroids within 3 months prior to screening.

  9. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in theopinion of the Investigator would compromise subject safety or interfere with theevaluations, or a QTc > 440 ms for males and > 460 ms for females using Fredericiaformula.

  10. Subjects receiving beta blocker via any route or who may require beta blockersduring the study.

  11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism,uncontrolled diabetes, paradoxical bronchospasm.

  12. History of malignancies.

  13. History of alcohol or drug abuse.

  14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening.

  15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton,theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening.

  16. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinicantagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE,anti-IL5/5R, anti-IL4R, high dose ICS, or systemic corticosteroid for treatment ofasthma within 6 months prior to screening.

  17. Known Human Immunodeficiency Virus (HIV)-positive status.

  18. Participated in any interventional clinical trials within 1 month prior toscreening.

  19. Pregnancy or breast feeding.

Study Design

Total Participants: 148
Treatment Group(s): 5
Primary Treatment: Albuterol Sulfate inhalation Placebo
Phase:
Study Start date:
August 15, 2022
Estimated Completion Date:
June 30, 2025

Study Description

This study will be conducted using the single-dose, randomized, double-blind, double-dummy, four-sequence, four-treatment, and multiple-center study design to evaluate the PD bioequivalence between the test albuterol sulfate (T) inhalation aerosol 108 mcg per actuation (eq. to albuterol base 90 mcg/puff) and the reference albuterol sulfate (R) (ProAir HFA or FDA authorized generic: Albuterol Sulfate HFA [Teva Pharmaceutical USA, Inc.]) inhalation aerosol 108 mcg per actuation (equal to albuterol base 90 mcg/puff). The two products will be studied using a crossover design in patients with stable mild asthma by administering a minimum of 3 doses of reference product (0, 90, 180 mcg albuterol) and 2 doses of test product (0, 90 mcg albuterol). The bronchodilation potency of albuterol sulfate are measured by the inhibition effects of methacholine challenge on the bronchodilation, as indicated by increase in the provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20).

Connect with a study center

  • Dr. Jivraj Mehta Smarak Health Foundation

    Ahmedabad, 38007
    India

    Site Not Available

  • KLEs Dr Prabhakar Kore Hospital & MRC

    Belagave, 590010
    India

    Site Not Available

  • Medical College and Hospital

    Kolkata, 700073
    India

    Site Not Available

  • NRS Medical College and Hospital

    Kolkata, 700014
    India

    Site Not Available

  • Aakash Healthcare Super Specialty Hospital

    New Delhi, 110075
    India

    Site Not Available

  • Kothrud Hospital

    Pune, 411038
    India

    Site Not Available

  • Pimpri Chinchwad Municipal Corporation Post Graduate Institute Yashwantrao Chavan Memorial Hospital

    Pune, 411018
    India

    Site Not Available

  • Ashirwad Hospital and Research Centre

    Ulhasnagar, 421004
    India

    Site Not Available

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807
    Taiwan

    Active - Recruiting

  • Tamshui Mackay Memorial Hospital

    New Taipei City, 251
    Taiwan

    Active - Recruiting

  • Shin Kong Wu Ho-Su Memorial Hospital

    Taipei City, 111
    Taiwan

    Active - Recruiting

  • Taipei Medical University Hospital

    Taipei City, 110
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.